Voluntary announcement on-market share repurchase
Filed with HKEX · Stock code 3696 · · 2 pages · English
Summary by 6ix AI
InSilico Medicine Cayman TopCo has announced a voluntary share repurchase plan to buy back shares on the open market. The board believes this action will enhance shareholder value and reflects confidence in the company's prospects. As of now, no shares have been repurchased under this mandate.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
InSilico Medicine Cayman TopCo on 6ix
Earlier from InSilico Medicine Cayman TopCo
- Grant of restricted share units
- Voluntary announcement InSilico Medicine reports preliminary positive first-in-human clinical trial data for ISM6331 designed using generative AI in mesothelioma and other solid tumors at esmo 2026
- Voluntary announcement InSilico Medicine triggers a milestone payment in AI-driven R&D collaboration with Servier for achieving early drug discovery milestone
- Voluntary announcement InSilico Medicine nominates peripheral-restricted VAV1 molecular glue degrader for potential treatment of autoimmune diseases
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Later from InSilico Medicine Cayman TopCo
- Discloseable transaction participation in the establishment of an investment fund
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow InSilico Medicine Cayman TopCo into a list and get an email when it puts out news.
Follow InSilico Medicine Cayman TopCo